The burgeoning landscape of innovative treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the read more GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting considerable weight loss – they exhibit intriguing con